10-Q: NRC Health Q2 Profit Plunges Amid Revenue Dip

National Research Corporation reported a significant decline in second-quarter net income and revenue, impacted by substantial executive compensation expenses, despite sequential improvements in recurring contract value.

Summary

• Net income for the six months ended June 30, 2025, decreased by 54.7% to $5.68 million from $12.53 million in the prior year.
• Revenue for the six months ended June 30, 2025, declined by 4% to $67.59 million from $70.33 million in the same period of 2024.
• Operating income for the six months ended June 30, 2025, fell by 42% to $10.18 million, with operating margin decreasing from 25% to 15%.
• Cash provided by operating activities significantly decreased by 71% to $5.51 million for the six months ended June 30, 2025, compared to $18.82 million in the prior year.
• Total Recurring Contract Value (TRCV) at June 30, 2025, was $136.95 million, a 1% decrease from $138.43 million at June 30, 2024, though it increased sequentially in Q1 and Q2 2025.
• Selling, general, and administrative expenses increased by 25% for the six months, primarily due to $6.6 million in cash bonuses and $571,000 in non-cash share-based compensation for executive leaders.
• A new credit agreement was entered into in February 2025, including a $30.0 million revolving credit facility and a $110.0 million delayed draw-down term facility, increasing notes payable to $77.03 million from $57.90 million.
• The company repurchased 381,736 shares of common stock for $5.8 million in Q2 2025 under a new $20 million authorization.
• Dividends of $5.5 million were paid in the first six months of 2025, with $2.8 million declared in Q2 2025 and paid in July 2025.

Sentiment

Score: 3

Explanation: The company experienced significant declines in revenue, net income, operating income, and cash flow from operations, largely due to substantial executive compensation expenses. While there are some positive indicators like sequential TRCV growth and a new credit facility, the overall financial performance is weak and raises concerns about profitability and efficiency.

Positives

• Total Recurring Contract Value (TRCV) increased sequentially in the first and second quarters of 2025, indicating improved sales and retention after prior declines.
• The retention rate increased by 2% in the six-month period ending June 30, 2025, compared to the same period in 2024.
• The working capital deficit improved to $10.6 million at June 30, 2025, from $16.3 million at December 31, 2024.
• A new credit agreement provides significant liquidity, including a $30.0 million revolving credit facility and a $110.0 million delayed draw-down term facility, with $27.6 million available on the term loan and $30.0 million on the revolving loan at June 30, 2025.
• The company remains in compliance with all financial covenants under its new credit agreement as of June 30, 2025.
• Workforce reduction and automation efforts implemented in Q4 2024 led to decreased salary and benefit costs in direct expenses.
• The company continues to invest in innovative solutions and product development, including building renovations to its headquarters completed in 2025.

Negatives

• Net income decreased by 54.7% to $5.68 million for the six months ended June 30, 2025, compared to $12.53 million in the prior year.
• Revenue decreased by 4% to $67.59 million for the six months ended June 30, 2025, primarily due to a $3.4 million decrease in recurring revenue from the existing client base.
• Operating income declined by 42% to $10.18 million, and operating margin decreased from 25% to 15% for the six months ended June 30, 2025.
• Cash provided by operating activities decreased significantly by 71% to $5.51 million for the six months ended June 30, 2025.
• Selling, general, and administrative expenses increased by 25% for the six months, largely due to $6.6 million in cash bonuses and increased non-cash share-based compensation for executive leaders.
• Total Recurring Contract Value (TRCV) at June 30, 2025, was lower by 1% compared to June 30, 2024, primarily due to insufficient growth in new contracts to offset losses.
• Total other expense increased by 70% for the six months, mainly due to higher interest expense of $772,000 from increased borrowings on the Delayed Draw Term Loan.
• The effective tax rate increased to 32% for the six months ended June 30, 2025, from 24% in the prior year, mainly due to deductible limitations on executive compensation related to cash bonuses.
• Increased debt from the new credit agreement, with notes payable rising to $77.03 million from $57.90 million.

Risks

• Possibility of non-renewal of client service contracts, reductions in services purchased or prices, and failure to retain key clients.
• Ability to compete in highly competitive markets, with potential for increased price pressure and expenses from new market entrants.
• Solutions and technology may not perform as expected.
• Acquisitions and partnerships may not achieve expected increased demand or profitability.
• Adverse effects of a pandemic on operations, sales, earnings, financial condition, and liquidity.
• Adverse effects of global conflicts on operations, sales, earnings, financial condition, and liquidity.
• Impact of an economic downturn.
• Impact of consolidation in the healthcare industry.
• Impact of federal healthcare and budget legislation, executive orders, cost-saving measures, and other regulatory changes.
• Ability to attract and retain key managers and other personnel.
• Intellectual property and other proprietary information technology could be copied or independently developed by competitors.
• Ability to maintain effective internal controls.
• Failures or deficiencies in the information technology platform.
• Potential for cyber-attacks, security breaches, or computer viruses affecting the company or its third-party providers.

Future Outlook

Management expects operating income and margin to increase in the near term, excluding the impact of executive compensation charges. Selling, general and administrative expenses are anticipated to increase in Q3 2025 due to executive compensation. Depreciation and amortization are also expected to increase due to continued software and intangible amortization, as well as depreciation on building renovations. Other expense is projected to rise in future periods due to additional borrowings on the Delayed Draw Term Loan. The company believes its existing liquidity sources will be sufficient to meet projected capital and debt maturity needs for the foreseeable future.

Management Comments

• Our purpose is to humanize healthcare and support organizations in their understanding of each unique individual.
• Our commitment to Human Understanding helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship.
• We believe that understanding the story is the key to unlocking the highest-quality and truly personalized care.
• We believe access to and analysis of our extensive consumer-driven information is increasingly valuable as healthcare providers need to better understand and engage the people they serve to create long-term relationships and build loyalty.
• We partner with clients across the continuum of healthcare services and believe this cross-continuum positioning is a unique and an increasingly important capability as evolving payment models drive healthcare providers and payers towards a more collaborative and integrated service model.
• We believe the expansion of our product and services portfolio during 2024, along with a broader sales effort, led to improved sales and retention in the fourth quarter compared with the prior several quarters.
• Generally, if we are able to sustain growth in TRCV, we would expect revenue growth to follow within the next few quarters (and vice versa). However, intervening events may affect this general expectation.
• While we continue to invest in product development and sales, our goal is to drive efficiencies and savings in overall costs to offset such investments.
• Our Board of Directors has established priorities for capital allocation, which prioritize funding of innovation and growth investments, including merger and acquisition activity as well as internal projects. The secondary priority is capital allocation for quarterly dividends and share repurchases.

Industry Context

National Research Corporation operates in the highly competitive healthcare analytics and patient experience market. The company's focus on 'Human Understanding' and end-to-end solutions aims to differentiate it by providing longitudinal insights into patient and employee experiences, which is increasingly critical as healthcare providers seek to build long-term relationships and loyalty amidst evolving payment models. The industry is experiencing consolidation, which could impact the company's client base and competitive landscape. The company's strategy to expand its product and services portfolio and invest in innovation aligns with broader industry trends emphasizing value-based care and patient engagement.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.
• The company's performance metrics, such as declining revenue and net income, suggest underperformance relative to a growth-oriented industry, especially when compared to companies successfully leveraging data analytics and AI in healthcare to drive efficiency and patient outcomes.
• Without specific industry benchmarks or competitor data within the filing, a direct quantitative comparison is not feasible.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in certain claims and litigation arising in the normal course of business.
• Management assesses the probability of loss and recognizes a liability when a loss is probable and estimable.
• The final disposition of claims at June 30, 2025, is not expected to have a material adverse effect on consolidated financial position, results of operations, or liquidity.
• Legal proceedings can impose significant burden on management and employees, include costly defense and settlement costs, and could harm reputation and brand.

Stakeholder Impact

• Shareholders: Impacted by significant decline in net income and EPS, increased debt, but also by continued dividend payments and share repurchase program. The new CEO and strategic investments could offer long-term value.
• Employees: Workforce reduction and automation implemented in Q4 2024 impacted some employees. New executive compensation arrangements benefit leadership.
• Customers: Continued investment in "Human Understanding" solutions aims to provide innovative services and improve client relationships and loyalty.
• Creditors: New credit agreement increases debt, but the company reports compliance with financial covenants, indicating ability to meet obligations.

Next Steps

• Continue to invest in providing innovative solutions to clients.
• Drive efficiencies and savings in overall costs to offset investments in product development and sales.
• Fund estimated future costs of $2.7 million in 2025 for headquarters building renovations through operating cash flows and borrowings on the Revolving Loan and Delayed Draw Term Loan.
• Evaluate the full effects of the "One Big Beautiful Bill Act" on estimated annual effective tax rate and cash tax position.
• Consider quarterly dividend declarations by the board of directors.
• Potentially utilize the accordion feature of the Delayed Draw Term Loan for future business acquisitions, stock repurchases, capital expenditures, or dividends.

Key Dates

Recommendation

The significant decline in net income, revenue, operating income, and cash flow from operations for the six months ended June 30, 2025, indicates a deteriorating financial performance. The substantial increase in selling, general, and administrative expenses, largely driven by executive cash bonuses, raises concerns about cost control and management's focus on shareholder value. While the sequential improvement in Total Recurring Contract Value and the new credit facility offer some strategic flexibility, the current financial trajectory is concerning. The increased debt burden, coupled with reduced profitability, suggests a higher risk profile. A seasoned investor would likely view these results as a strong signal to sell, as the current financial health does not support a positive outlook despite management's optimistic statements about future growth and efficiency.

Keywords

Healthcare Analytics, Patient Experience, Employee Engagement, Corporate Governance, SEC Filing, 10-Q, Financial Results, Stock Repurchase, Executive Compensation, Debt Financing, National Research Corporation, NRC Health, Healthcare Technology, Customer Loyalty, Risk Management